Merck Units To Pay $44M In Rebif Whistleblower Suit

Law360, New York (May 4, 2011, 5:53 PM EDT) -- Merck KGaA affiliates have agreed to pay $44.3 million to resolve a whistleblower’s allegations that they bought off health care providers to promote or prescribe the multiple sclerosis drug Rebif, resulting in tainted Medicare and Medicaid claims, federal authorities announced Wednesday.

The agreement with pharmaceutical manufacturers Serono Laboratories Inc., EMD Serono Inc., Merck Serono SA, and Ares Trading SA also settles a False Claims Act suit that whistleblower Tim Amato lodged against the companies in Maryland federal court in 2005.

Amato, who worked as a regional...
To view the full article, register now.




Case Information

Case Title

United States of America ex rel. Tim Amato v. Serono Laboratories, Inc. et al

Case Number




Nature of Suit

Other Statutory Actions


Richard D Bennett

Date Filed

December 29, 2005


UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.